Does Blue Cross Blue Shield of Minnesota Cover Farxiga?

What Farxiga Is and Why Coverage Decisions Are Complex

Farxiga (dapagliflozin 5 mg and 10 mg tablets) is a sodium-glucose cotransporter-2 (SGLT2) inhibitor manufactured by AstraZeneca. The FDA granted initial approval in January 2014 for type 2 diabetes mellitus (T2DM), then expanded the label in 2020 to include heart failure with reduced ejection fraction (HFrEF), and again in 2021 for chronic kidney disease (CKD) regardless of whether diabetes is present [1]. Each indication carries its own set of clinical criteria, and BCBS MN evaluates each one separately when processing a prior authorization (PA) request.

Why BCBS MN Plans Differ From Each Other

BCBS MN is not a single formulary. It operates dozens of distinct plan products, commercial employer-sponsored plans, individual Marketplace plans, Medicare Advantage (Blue Cross Medicare Advantage), and state public-program contracts. Each product has its own drug list, tier structure, and PA rules. A member on the Aware PPO may face different cost-sharing than someone enrolled in the Blue Plus HMO. Always check your specific Evidence of Coverage (EOC) document or call the pharmacy benefits number on your insurance card before assuming coverage.

The Three FDA-Approved Indications and Their Clinical Weight

The breadth of Farxiga's approved indications matters when building a PA. Physicians and patients should know which label applies to their situation:

• Type 2 diabetes: Farxiga reduces HbA1c by approximately 0.8 to 0.9 percentage points as monotherapy [2]. DECLARE-TIMI 58 (N=17,160, median follow-up 4.2 years) showed dapagliflozin reduced the composite of hospitalization for heart failure or cardiovascular death by 17% compared with placebo in patients with T2DM and high cardiovascular risk [3].
• Heart failure (HFrEF): DAPA-HF (N=4,744) demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death vs. Placebo (hazard ratio 0.74; 95% CI 0.65 to 0.83; P<0.001), with benefit seen regardless of diabetes status [4].
• Chronic kidney disease: DAPA-CKD (N=4,304) showed a 39% reduction in the composite of sustained eGFR decline of 50% or more, end-stage kidney disease, or renal/cardiovascular death vs. Placebo (hazard ratio 0.61; 95% CI 0.51 to 0.73; P<0.001) [5].

These trial results directly inform what BCBS MN's clinical reviewers look for during PA review. A PA submitted for a patient with eGFR of 28 and urine albumin-to-creatinine ratio (UACR) above 200 mg/g citing DAPA-CKD data will carry more weight than a vague request.

How BCBS MN Formularies Classify Farxiga

Typical Tier Placement

On most BCBS MN commercial plans, Farxiga sits at Tier 2 (preferred brand) or Tier 3 (non-preferred brand). Tier placement determines your copay or coinsurance:

• Tier 2: Typical member cost $50, $100 per 30-day fill after deductible.
• Tier 3: Typical member cost $100, $200 per 30-day fill, sometimes 30 to 40% coinsurance on plans without flat copays.

Medicare Advantage plans follow CMS Part D tier rules. Under Part D, Farxiga is commonly placed at Tier 3 or Tier 4 (non-preferred) on many stand-alone or MA-PD formularies, though exact placement shifts annually during the October plan year update [6].

Step Therapy Requirements

For the T2DM indication, most BCBS MN plans impose step therapy. This typically means the member must have tried and either failed or had a documented contraindication to at least one of the following before Farxiga is approved:

1. Metformin (generic, widely available at low cost)
2. A sulfonylurea (e.g., glipizide, glimepiride)

The American Diabetes Association's 2024 Standards of Care specify that for patients with T2DM and established cardiovascular disease, heart failure, or CKD, an SGLT2 inhibitor or GLP-1 receptor agonist should be added "regardless of HbA1c" and "independent of baseline HbA1c or individualized HbA1c target" [7]. Citing this guideline language in a PA letter can waive the step-therapy requirement when a patient has a compelling cardiovascular or renal indication.

Prior Authorization Criteria: What BCBS MN Reviewers Look For

Although BCBS MN does not publish every internal PA criterion publicly, standard commercial payer criteria for SGLT2 inhibitors typically include:

• Confirmed T2DM diagnosis (ICD-10: E11.xx), HFrEF (I50.2x), or CKD (N18.x) consistent with the FDA label
• HbA1c documentation (often HbA1c >7.0% for diabetes PAs)
• eGFR and UACR lab values for CKD or heart failure PAs
• Prescriber attestation that the drug will be used on-label
• Failure of, or contraindication to, step-therapy agents (T2DM indication)

The FDA label itself states Farxiga should not be initiated when eGFR is <25 mL/min/1.73 m² for the diabetes indication, though it may be continued for cardiorenal protection at lower eGFR ranges per updated prescribing information [1]. Including current eGFR in the PA documentation avoids automatic denial on safety grounds.

How to Get Farxiga Approved Under BCBS MN

Step 1: Confirm Your Plan's Formulary in Writing

Log into your BCBS MN member portal or call the pharmacy benefits number (printed on your card). Request a Formulary Drug List and confirm:

• Is dapagliflozin (Farxiga) listed?
• What tier is it on?
• Is PA required?
• Is step therapy required?

Download or screenshot the formulary page with a date stamp. This becomes evidence if you later need to appeal.

Step 2: Have Your Prescriber Submit a Complete PA

A complete PA submission for BCBS MN typically requires a PA request form (available on the BCBS MN provider portal), along with supporting clinical documentation. The documentation should include your most recent HbA1c (within 90 days for diabetes PAs), eGFR and UACR results, echocardiographic data confirming reduced ejection fraction if submitting under HFrEF, and a brief clinical narrative tying your diagnosis to the relevant FDA indication.

Incomplete PAs are the single most common reason for initial denial. A study published in JAMA Internal Medicine found that prior authorization delays were associated with treatment abandonment in 19% of cases for high-cost branded medications [8]. Submitting complete documentation on the first attempt reduces this risk.

Step 3: Request an Expedited Review if Clinically Urgent

BCBS MN, like all insurers subject to Minnesota Department of Commerce oversight, must respond to standard PA requests within 3 business days and expedited requests within 24 hours when delay could "seriously jeopardize the enrollee's life or health." If a patient is being discharged from a hospital after an HFrEF admission and Farxiga is part of the discharge regimen, an expedited PA is clinically justified.

Step 4: Appeal a Denial

If BCBS MN denies the PA:

1. Request the denial letter with the specific clinical criteria used.
2. Have your prescriber write a peer-to-peer appeal, citing the trial data (DAPA-HF, DAPA-CKD, or DECLARE-TIMI 58) relevant to your diagnosis.
3. If the internal appeal fails, Minnesota law provides the right to an external review by an Independent Review Organization (IRO) within 60 days of denial.

The American Heart Association's 2022 position statement on access to heart failure therapies states: "Clinicians should advocate vigorously for patients when formulary restrictions impede access to guideline-directed medical therapy" [9]. Documenting that Farxiga is guideline-directed therapy (ADA 2024, ACC/AHA 2022 Heart Failure Guidelines) strengthens an appeal substantially.

Cost and Patient Assistance Options When Coverage Falls Short

AstraZeneca's Farxiga Savings Program

AstraZeneca operates the Farxiga Savings Card program for commercially insured patients. Eligible patients with commercial (non-government) insurance may pay as little as $0 per month with a maximum savings of approximately $150 per fill. This card cannot be used by Medicare or Medicaid beneficiaries due to federal anti-kickback provisions.

AstraZeneca Patient Assistance Program (AZ&ME)

Uninsured or underinsured patients with household income below a defined threshold (typically 400% of the federal poverty level) may qualify for free Farxiga through the AZ&ME Prescription Savings program. Applications are available at AstraZeneca's patient assistance portal. Processing typically takes 2 to 4 weeks.

Minnesota RxConnect and State Pharmaceutical Assistance

Minnesota does not operate a state pharmaceutical assistance program (SPAP) for working-age adults as of 2025. However, individuals who qualify for Medical Assistance (Minnesota Medicaid) or MinnesotaCare may have Farxiga covered under those programs' formularies, subject to the state's preferred drug list managed by the Department of Human Services.

GoodRx and Mark Cuban Cost Plus Drugs

GoodRx coupons for Farxiga 10 mg (30 tablets) typically show cash prices of $540, $590 at Minnesota pharmacies, offering minimal savings over the retail price since no generic dapagliflozin is available in the US market as of mid-2025. Mark Cuban's Cost Plus Drugs platform does not currently list branded Farxiga.

The Clinical Evidence That Supports Medical Necessity Arguments

The framework below is designed to help prescribers match the right trial to the right PA narrative. BCBS MN reviewers and external IRO physicians recognize landmark trial names. Using trial-specific language shifts a PA from a generic request to a documented clinical necessity argument.

Cardiovascular Protection in T2DM: DECLARE-TIMI 58

DECLARE-TIMI 58 enrolled 17,160 patients with T2DM and either established atherosclerotic cardiovascular disease (ASCVD) or multiple cardiovascular risk factors. Over a median 4.2 years, dapagliflozin reduced hospitalization for heart failure by 27% vs. Placebo (HR 0.73; 95% CI 0.61 to 0.88) [3]. For a PA in a patient with T2DM and documented coronary artery disease or peripheral artery disease, this trial is the primary citation.

Heart Failure Regardless of Diabetes: DAPA-HF

DAPA-HF showed benefit in patients without diabetes as well as those with T2DM, which is clinically significant for BCBS MN PAs because the FDA label explicitly covers HFrEF patients regardless of glycemic status [4]. Echocardiographic confirmation of EF <40%, current NYHA class II, IV symptoms, and documentation of optimal background therapy (ACE inhibitor/ARB/ARNI plus beta-blocker) support medical necessity when Farxiga is added as quadruple therapy per the 2022 ACC/AHA/HFSA Heart Failure Guidelines [10].

Kidney Protection: DAPA-CKD

DAPA-CKD enrolled patients with eGFR 25 to 75 mL/min/1.73 m² and UACR 200 to 5,000 mg/g. The 39% reduction in the primary composite endpoint was consistent across subgroups with and without T2DM [5]. KDIGO 2022 guidelines recommend SGLT2 inhibitors for patients with CKD and eGFR >20 mL/min/1.73 m² with UACR >200 mg/g [11]. Including the KDIGO recommendation alongside DAPA-CKD data in a PA letter directly addresses the clinical reviewer's two key questions: Is this on-label? Does evidence of benefit exist?

What to Do If You Are Currently Paying Out of Pocket

If your PA is pending or you are between coverage periods, several options exist to bridge the gap:

1. AstraZeneca Starter Sample: Ask your prescriber for a sample pack. AstraZeneca provides 30-day sample supplies through physician offices, allowing uninterrupted therapy during the PA review period.
2. Split the Indication: If you have both T2DM and CKD, your prescriber can choose the CKD indication for the PA, which often has a less restrictive step-therapy requirement since metformin is not approved for CKD with eGFR <30.
3. Pharmacist-Initiated PA: In Minnesota, pharmacists have limited authority to initiate PA requests for some medications. Ask your pharmacist whether this applies to your plan.
4. Urgent Formulary Exception: If your plan's formulary lists a competing SGLT2 inhibitor (e.g., empagliflozin) at a lower tier, but your prescriber has a specific clinical reason for Farxiga, a formulary exception request with clinical justification can sometimes achieve Tier 2 pricing.

Safety Profile Relevant to Insurance Coverage and Clinical Use

BCBS MN's PA criteria sometimes include safety exclusions. Common contraindications and warnings that reviewers may flag:

• Diabetic ketoacidosis (DKA) risk: Farxiga carries an FDA boxed warning for DKA, primarily in type 1 diabetes. Farxiga is not approved for T1DM. A claim with a T1DM diagnosis code (E10.xx) will be denied on safety grounds [1].
• eGFR threshold: The diabetes indication should not be initiated with eGFR <25 mL/min/1.73 m². The CKD indication lower bound is eGFR >20 mL/min/1.73 m² [1].
• Genital mycotic infections: Clinical trials reported genital mycotic infections in approximately 6 to 8% of women and 3% of men on dapagliflozin vs. 1 to 2% on placebo [2]. This is a monitoring issue, not a coverage exclusion, but may be documented in the prescriber's clinical narrative to demonstrate awareness of risk management.
• Amputation risk: Unlike canagliflozin (which carries an FDA boxed warning for lower-limb amputation), dapagliflozin does not carry this warning, a distinction that may be relevant for patients with peripheral artery disease [1].

The FDA's prescribing information for Farxiga, available at the FDA's Drugs@FDA database, remains the authoritative source for label-specific safety data [1].

Monitoring Requirements After Coverage Is Secured

Once BCBS MN approves Farxiga and the patient begins therapy, ongoing monitoring supports both clinical safety and continued PA renewals (many plans require annual re-authorization):

• HbA1c: Every 3 months until stable, then every 6 months for the T2DM indication. Target HbA1c is individualized per ADA 2024 Standards of Care [7].
• eGFR and serum creatinine: At baseline, at 2 to 3 months after initiation, and then annually or per CKD staging.
• Blood pressure: Dapagliflozin produces a modest blood pressure reduction of approximately 2 to 3 mmHg systolic in clinical trials [2], which may affect antihypertensive regimen adjustments.
• Urinalysis: Monitoring for asymptomatic bacteriuria or genital infection signs, particularly in the first 3 to 6 months.

Documenting these labs in the medical record ensures that when a PA renewal is required, your prescriber has the data readily available to demonstrate ongoing clinical benefit and appropriate safety monitoring.